Literature DB >> 9452307

Overexpression of fragile X gene (FMR-1) transcripts increases cAMP production in neural cells.

E Berry-Kravis1, R Ciurlionis.   

Abstract

Fragile X syndrome results from amplification of an unstable trinucleotide (CGG) repeat in the first exon of FMR-1, the "fragile X gene." This mutation silences the gene, resulting in loss of expression of the FMR proteins (FMRP), a series of RNA-binding proteins generated by alternative splicing of FMR-1 transcripts. We have shown that cAMP production is diminished in cells from patients with fragile X syndrome. To establish a direct relationship between FMR-1 expression and cAMP metabolism, FMRP isoforms 1 and 7 were overexpressed in the neurotumor hybrid cell line HN2. Cyclic AMP production in clonal HN2 lines overexpressing FMRP was significantly higher than in nonoverexpressing control lines and increased with increasing total FMR-1 mRNA on Northern blots and FMRP signal on Western blots. These data support a role for FMRP in the regulation of cAMP signal transduction by increasing intracellular cAMP, perhaps through a mechanism involving binding and enhanced translation of mRNA(s) for cAMP cascade proteins. Diminished cAMP production in the absence of FMR-1 may provide one neurochemical mechanism through which FMR-1 influences cognitive function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9452307     DOI: 10.1002/(SICI)1097-4547(19980101)51:1<41::AID-JNR4>3.0.CO;2-L

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  20 in total

1.  Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment.

Authors:  Catherine H Choi; Brian P Schoenfeld; Aaron J Bell; Paul Hinchey; Maria Kollaros; Michael J Gertner; Newton H Woo; Michael R Tranfaglia; Mark F Bear; R Suzanne Zukin; Thomas V McDonald; Thomas A Jongens; Sean M J McBride
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

Review 2.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

3.  PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.

Authors:  Catherine H Choi; Brian P Schoenfeld; Eliana D Weisz; Aaron J Bell; Daniel B Chambers; Joseph Hinchey; Richard J Choi; Paul Hinchey; Maria Kollaros; Michael J Gertner; Neal J Ferrick; Allison M Terlizzi; Nicole Yohn; Eric Koenigsberg; David A Liebelt; R Suzanne Zukin; Newton H Woo; Michael R Tranfaglia; Natalia Louneva; Steven E Arnold; Steven J Siegel; Francois V Bolduc; Thomas V McDonald; Thomas A Jongens; Sean M J McBride
Journal:  J Neurosci       Date:  2015-01-07       Impact factor: 6.167

4.  Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.

Authors:  Elizabeth M Berry-Kravis; Mark D Harnett; Scott A Reines; Melody A Reese; Lauren E Ethridge; Abigail H Outterson; Claire Michalak; Jeremiah Furman; Mark E Gurney
Journal:  Nat Med       Date:  2021-04-29       Impact factor: 53.440

5.  Drosophila mutants of the autism candidate gene neurobeachin (rugose) exhibit neuro-developmental disorders, aberrant synaptic properties, altered locomotion, and impaired adult social behavior and activity patterns.

Authors:  Alexandria Wise; Luis Tenezaca; Robert W Fernandez; Emma Schatoff; Julian Flores; Atsushi Ueda; Xiaotian Zhong; Chun-Fang Wu; Anne F Simon; Tadmiri Venkatesh
Journal:  J Neurogenet       Date:  2015-07-14       Impact factor: 1.250

Review 6.  Epac2-mediated dendritic spine remodeling: implications for disease.

Authors:  Peter Penzes; Kevin M Woolfrey; Deepak P Srivastava
Journal:  Mol Cell Neurosci       Date:  2010-11-27       Impact factor: 4.314

7.  The fragile X mental retardation protein developmentally regulates the strength and fidelity of calcium signaling in Drosophila mushroom body neurons.

Authors:  Charles R Tessier; Kendal Broadie
Journal:  Neurobiol Dis       Date:  2010-09-16       Impact factor: 5.996

8.  GABAergic circuit dysfunction in the Drosophila Fragile X syndrome model.

Authors:  Cheryl L Gatto; Daniel Pereira; Kendal Broadie
Journal:  Neurobiol Dis       Date:  2014-01-12       Impact factor: 5.996

9.  Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse.

Authors:  Haruki Higashimori; Lydie Morel; James Huth; Lothar Lindemann; Chris Dulla; Amaro Taylor; Mike Freeman; Yongjie Yang
Journal:  Hum Mol Genet       Date:  2013-02-07       Impact factor: 6.150

Review 10.  The cyclic AMP phenotype of fragile X and autism.

Authors:  Daniel J Kelley; Anita Bhattacharyya; Garet P Lahvis; Jerry C P Yin; Jim Malter; Richard J Davidson
Journal:  Neurosci Biobehav Rev       Date:  2008-06-17       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.